IL321414A - Vaccines against respiratory diseases - Google Patents

Vaccines against respiratory diseases

Info

Publication number
IL321414A
IL321414A IL321414A IL32141425A IL321414A IL 321414 A IL321414 A IL 321414A IL 321414 A IL321414 A IL 321414A IL 32141425 A IL32141425 A IL 32141425A IL 321414 A IL321414 A IL 321414A
Authority
IL
Israel
Prior art keywords
respiratory diseases
vaccines against
against respiratory
vaccines
diseases
Prior art date
Application number
IL321414A
Other languages
Hebrew (he)
Inventor
Damon Andrew Hollands Berman
Ye Che
Alexey Vyacheslavovitch Gribenko
Bridget Yih Jiin Huang
Weiqiang Li
Yan Li
Kena Anne Swanson
Helen Chen Wang
Sabine Susanne Wellnitz
Kam Ho Wong
Qi Yang
Aiping Zhu
Original Assignee
Pfizer
Damon Andrew Hollands Berman
Ye Che
Alexey Vyacheslavovitch Gribenko
Bridget Yih Jiin Huang
Weiqiang Li
Yan Li
Kena Anne Swanson
Helen Chen Wang
Sabine Susanne Wellnitz
Kam Ho Wong
Qi Yang
Aiping Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Damon Andrew Hollands Berman, Ye Che, Alexey Vyacheslavovitch Gribenko, Bridget Yih Jiin Huang, Weiqiang Li, Yan Li, Kena Anne Swanson, Helen Chen Wang, Sabine Susanne Wellnitz, Kam Ho Wong, Qi Yang, Aiping Zhu filed Critical Pfizer
Publication of IL321414A publication Critical patent/IL321414A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL321414A 2023-01-18 2025-06-10 Vaccines against respiratory diseases IL321414A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363480504P 2023-01-18 2023-01-18
US202363586506P 2023-09-29 2023-09-29
US202363610006P 2023-12-14 2023-12-14
US202363611808P 2023-12-19 2023-12-19
PCT/IB2024/050404 WO2024154048A1 (en) 2023-01-18 2024-01-16 Vaccines against respiratory diseases

Publications (1)

Publication Number Publication Date
IL321414A true IL321414A (en) 2025-08-01

Family

ID=89661946

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321414A IL321414A (en) 2023-01-18 2025-06-10 Vaccines against respiratory diseases

Country Status (12)

Country Link
US (1) US20240252614A1 (en)
EP (1) EP4651889A1 (en)
JP (1) JP2026504862A (en)
KR (1) KR20250122511A (en)
CN (1) CN120548194A (en)
AU (1) AU2024209772A1 (en)
CO (1) CO2025009576A2 (en)
IL (1) IL321414A (en)
MX (1) MX2025008379A (en)
PE (1) PE20252308A1 (en)
TW (1) TW202436325A (en)
WO (1) WO2024154048A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025119162A1 (en) * 2023-12-04 2025-06-12 深圳深信生物科技有限公司 Metapneumovirus (mpv) vaccine
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP5639338B2 (en) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド Liposome production system and production method
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
PL2445526T3 (en) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
PT2988780T (en) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Stabilized soluble prefusion rsv f polypeptides
CN105408348B (en) 2013-06-17 2021-07-06 扬森疫苗与预防公司 Stabilized soluble prefusion RSV F polypeptide
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
US10420834B2 (en) 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
CN107847580B (en) 2015-07-07 2022-08-12 扬森疫苗与预防公司 Vaccines against RSV
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
RU2723039C2 (en) 2015-12-23 2020-06-08 Пфайзер Инк. Protein f rsv mutants
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
WO2018081289A2 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion piv f immunogens and their use
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
KR20220010478A (en) 2019-05-20 2022-01-25 발네바 에스이 Subunit vaccines for the treatment or prevention of respiratory tract infections
US12679870B2 (en) 2020-04-29 2026-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant human metapneumovirus F proteins and their use
EP4171627A1 (en) 2020-06-29 2023-05-03 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
IL320367A (en) 2020-10-09 2025-06-01 Univ Texas Pre-stabilized HMPV F proteins
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
KR20230167017A (en) 2021-04-09 2023-12-07 발네바 에스이 Human metapneumovirus vaccine
AR127808A1 (en) 2021-11-30 2024-02-28 Sanofi Pasteur Inc VACCINES AGAINST THE HUMAN METAPNEUMOVIRUS
JP2024544054A (en) 2021-11-30 2024-11-27 サノフィ パスツール インコーポレイテッド Viral vector-based vaccine for human metapneumovirus
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
AU2023269241A1 (en) 2022-05-12 2024-11-21 Msd International Business Gmbh Stabilized pre-fusion hmpv fusion proteins

Also Published As

Publication number Publication date
KR20250122511A (en) 2025-08-13
EP4651889A1 (en) 2025-11-26
US20240252614A1 (en) 2024-08-01
JP2026504862A (en) 2026-02-10
MX2025008379A (en) 2025-08-01
TW202436325A (en) 2024-09-16
PE20252308A1 (en) 2025-09-22
WO2024154048A1 (en) 2024-07-25
CO2025009576A2 (en) 2025-08-08
AU2024209772A1 (en) 2025-06-26
CN120548194A (en) 2025-08-26

Similar Documents

Publication Publication Date Title
SG11202012021UA (en) Interface assemblies for respiratory therapy
EP3927405A4 (en) ADJUSTABLE EXPIRATORY RELEASE IN RESPIRATORY THERAPY
EP4034550A4 (en) VACCINE THERAPY FOR RAN PROTEIN DISEASES
CA204343S (en) Inhaler
CA193488S (en) Inhaler
EP4329849C0 (en) Inhaler
CA198068S (en) Inhaler
ZA201903426B (en) Oral vaccine against ruminant respiratory disease comprising polyvinylpyrrolidone
EP3755409A4 (en) Oro-nasal patient interface for treating sleep disordered breathing
EP4260722C0 (en) Inhaler
SG11202009955QA (en) Headgear for use with a patient interface of a respiratory therapy system
IL307268A (en) Combination therapy for covid-19 vaccination
GB202106160D0 (en) Inhaler
EP4410310A4 (en) Prophylactic or therapeutic agent for respiratory diseases
CA3280015A1 (en) Vaccines against respiratory diseases
GB202115132D0 (en) Inhaler
CA200217S (en) Inhaler
EP4744735A2 (en) MEDICAL FACE MASK
HUE065591T2 (en) Medicament for treating infectious diseases
GB202004337D0 (en) Inhaler
CA224059S (en) Inhaler
CA224060S (en) Inhaler
GB202315641D0 (en) Breathing airways
ZA202210371B (en) Backpack ventilator for preventing respiratory infectious diseases
CA209032S (en) Inhaler